Market Overview:
The global gastroparesis drugs market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of gastroparesis, rising awareness about the condition, and technological advancements in drug delivery systems. Based on type, prokinetic agents are expected to dominate the global gastroparesis drugs market during the forecast period. This is due to their ability to improve stomach emptying and reduce symptoms associated with gastroparesis. Based on application, diabetic gastroparesis is expected to be the largest segment of the global market during the forecast period. This is due to increased incidence of diabetes mellitus across all regions worldwide.
Product Definition:
Gastroparesis Drugs are used to treat Gastroparesis. Gastroparesis is a condition in which the stomach muscles do not work properly, causing food to move slowly or not at all through the stomach. This can lead to problems such as nausea, vomiting, bloating and feeling full after eating only a small amount of food.
Prokinetic Agents:
Prokinetic agents are used to treat conditions such as gastroparesis and gastroesophageal reflux disease (GERD). Prokinetic agents act by increasing the movement of food through the gastrointestinal tract. Some of these also reduce nausea and vomiting. They are used in various combinations with other drugs for treating different diseases related to stomach and intestine function.
Antiemetic Agents:
Antiemetic agents are used to prevent or reduce nausea and vomiting. Vomiting is caused by the movement of food through the stomach and into the intestine. Antiemetic drugs do not cure gastroparesis but they can help to control symptoms such as nausea, vomiting, abdominal pain, etc., thereby improving patient quality of life.
Application Insights:
On the basis of application, the global gastroparesis drugs market is segmented into diabetic gastroparesis and idiopathic gastroparesis. The diabetic gastroparesis segment held a major share in 2017 due to increasing prevalence of diabetes mellitus globally. According to WHO, approximately 9% of adults were diagnosed with diabetes in 2017 and this number is expected to reach 23% by 2050. Thus, growing incidence of diabetes will boost demand for new drugs during the forecast period.
The idiopathic Gastrointestinal (GI) motility disorder segment is expected to grow at a lucrative rate during the forecast period owing to lesser known causes leading to increased incidence rates as compared with other countries such as U.S.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to increasing prevalence of gastroparesis and other associated disorders, rising awareness about treatment options, availability of highly skilled physicians and advanced healthcare facilities as well as high health expenditure by government in this region. Moreover, presence of key pharmaceutical companies that are engaged in strategic initiatives for the development of new drugs will help increase demand for prokinetic agents and antiemetic agents over the forecast period.
Asia Pacific is expected to witness lucrative growth during the forecast period owing to rise in disposable income coupled with improvement in overall economic conditions which has led to an increase adoption of unhealthy eating habits such as late night snacking among individuals especially youth group thereby increasing risk factors such as obesity & diabetes leading to Gastroparesis (GP) or diabetic gastroparesis (DGP).
Growth Factors:
- Increasing incidence of gastroparesis
- Growing awareness about the symptoms and treatment of gastroparesis
- Rising demand for novel and effective therapies for gastroparesis
- Availability of government funding for research on gastroparesis drugs
- Growing number of clinical studies on new drug therapies for gastroparesis
Scope Of The Report
Report Attributes
Report Details
Report Title
Gastroparesis Drugs Market Research Report
By Type
Prokinetic Agents, Antiemetic Agents, Others
By Application
Diabetic Gastroparesis, Idiopathic Gastroparesis
By Companies
Sumitomo, Cadila Pharmaceuticals, Sanofi, Teva, Johnson & Johnson, Pfizer, Kyowa Kirin Pharmaceuticals, Hanmi Pharm, Ani Pharmaceuticals
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
183
Number of Tables & Figures
129
Customization Available
Yes, the report can be customized as per your need.
Global Gastroparesis Drugs Market Report Segments:
The global Gastroparesis Drugs market is segmented on the basis of:
Types
Prokinetic Agents, Antiemetic Agents, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Diabetic Gastroparesis, Idiopathic Gastroparesis
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Sumitomo
- Cadila Pharmaceuticals
- Sanofi
- Teva
- Johnson & Johnson
- Pfizer
- Kyowa Kirin Pharmaceuticals
- Hanmi Pharm
- Ani Pharmaceuticals
Highlights of The Gastroparesis Drugs Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Prokinetic Agents
- Antiemetic Agents
- Others
- By Application:
- Diabetic Gastroparesis
- Idiopathic Gastroparesis
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gastroparesis Drugs Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gastroparesis drugs are medications that help to slow down the stomach's emptying process. This can improve the symptoms of gastroparesis, such as nausea, vomiting, and diarrhea.
Some of the major players in the gastroparesis drugs market are Sumitomo, Cadila Pharmaceuticals, Sanofi, Teva, Johnson & Johnson, Pfizer, Kyowa Kirin Pharmaceuticals, Hanmi Pharm, Ani Pharmaceuticals.
The gastroparesis drugs market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gastroparesis Drugs Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Gastroparesis Drugs Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Gastroparesis Drugs Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Gastroparesis Drugs Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Gastroparesis Drugs Market Size & Forecast, 2020-2028
4.5.1 Gastroparesis Drugs Market Size and Y-o-Y Growth
4.5.2 Gastroparesis Drugs Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Prokinetic Agents
5.2.2 Antiemetic Agents
5.2.3 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Diabetic Gastroparesis
6.2.2 Idiopathic Gastroparesis
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gastroparesis Drugs Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gastroparesis Drugs Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Prokinetic Agents
9.6.2 Antiemetic Agents
9.6.3 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Diabetic Gastroparesis
9.10.2 Idiopathic Gastroparesis
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Prokinetic Agents
10.6.2 Antiemetic Agents
10.6.3 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Diabetic Gastroparesis
10.10.2 Idiopathic Gastroparesis
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Prokinetic Agents
11.6.2 Antiemetic Agents
11.6.3 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Diabetic Gastroparesis
11.10.2 Idiopathic Gastroparesis
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Prokinetic Agents
12.6.2 Antiemetic Agents
12.6.3 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Diabetic Gastroparesis
12.10.2 Idiopathic Gastroparesis
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Prokinetic Agents
13.6.2 Antiemetic Agents
13.6.3 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Diabetic Gastroparesis
13.10.2 Idiopathic Gastroparesis
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gastroparesis Drugs Market: Competitive Dashboard
14.2 Global Gastroparesis Drugs Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Sumitomo
14.3.2 Cadila Pharmaceuticals
14.3.3 Sanofi
14.3.4 Teva
14.3.5 Johnson & Johnson
14.3.6 Pfizer
14.3.7 Kyowa Kirin Pharmaceuticals
14.3.8 Hanmi Pharm
14.3.9 Ani Pharmaceuticals
